The purpose of the Clinical Advisory Committee (CAC) is to increase the efficiency, quality and effectiveness of the Medicaid healthcare system. CAC provides a process for physician/provider intervention to promote quality care, member safety, cost effectiveness and positive physician/provider relations through discussion about Medicaid benefits and healthcare services.
Upcoming CAC Meetings
After registering, you will receive a confirmation email containing information about joining the meeting.
- Anyone that would like to speak during the public comment period please complete the above CAC Disclosure Form and email it to CAC@hhs.iowa.gov
- Disclosure form submissions must be received no later than one week prior to the meeting date.
Contact: CAC@hhs.iowa.gov
Previous CAC Meeting Agendas and Minutes
CAC State Annual Reports
CAC Members
Committee Chair:
- Bill Jagiello, DO
Committee Members:
- Chitra Reddy, MD
- Dana Danley, MD
- Dawn Schwartz, ARNP
- Diana Smith, ARNP
- Geetanjali Sahu, MD
- Kartik Anand, MD
- Kelli Roenfanz, DO
- Polly Ferguson, MD
- Wendy Sanders, ARNP
Interested in serving as a CAC member? Click here for a Member Interest Form.
CAC Criteria Material Library
List items for Clinical Advisory Committee (CAC) Criteria Material Library
The purpose of the CAC Criteria Material Library is to provide documentation for physician and provider interventions regarding specific subject matters. Documents are reviewed at the CAC meeting or by specialists annually to ensure they continue to increase the efficiency, quality and effectiveness of the Medicaid healthcare system.
Chromosomal Microarray Analysis
Gene Expression Profiling for Management of Breast Cancer
Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome
Genetic Testing for Lynch Syndrome
Molecular Analysis for Targeted Therapy of Non-Small Cell Lung Cancer
Testing for Hereditary Cancer Susceptibility Syndromes Using Multi-Gene Panels
Adstiladrin (nadofaragene firadenovec-vncg)
Abecma (idecabtagene vicleucel)
Breyanzi (lisocabtagene maraleucel)
Carvykti (ciltacabtagene autoleucel)
Darzalex and Darzalex Faspro (daratumumab; daratumumab and hyaluronidase-fihj)
Elahere (mirvetuximab soravtansine-gynx)
Elfabrio (pegunigalsidase alfa-iwxj)
Enhertu (fam-trastuzumab deruxtecan-nxki)
Fyarro (sirolimus protein-bound particles)
Injectafer (ferric carboxymaltose)
Kadcyla (ado-trastuzumab emtansine)
Lutathera (lutetium Lu 177 dotatate)
Luxturna (voretigene neparvovec-rzyl)
Namenda (memantine) for Autism Spectrum Disorder
Natalizumab Agents (Tysabri, Tyruko)
Nexviazyme (avalglucosidase alfa-ngpt)
Opdualag (nivolumab and relatlimab-rmbw)
Padcev (enfortumab vedotin-ejfv)
Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
Rylaze [asparaginase erwinia chrysanthemi (recombinant)-rywn]
Rystiggo (rozanolixizumab-noli)
Spravato (esketamine nasal spray)
Tecartus (brexucabtagene autoleucel)
Trodelvy (sacituzumab govitecan-hziy)
Vitamin, Mineral, Amino Acid Supplements
Vyjuvek (beremagene geperpavec-svdt)
Vyvgart and Vyvgart Hytrulo (efgartigimod alfa-fcab; efgartigimod alfa and hyaluronidase-qvfc)
Xenpozyme (olipudase alfa-rpcp)
Yescarta (axicabtagene ciloleucel)
Zolgensma (onasemnogene abeparvovec-xioi)
Prior Authorization from Iowa Medicaid is required for certain services and supplies. For more information, please see the Prior Authorization webpage.
For telephone accessibility assistance, use the resources below.
-
Call Relay Iowa TTY
For telephone accessibility assistance if you are deaf, hard-of-hearing, deaf-blind, or have difficulty speaking.
-
ةیبرعلا | 简体中文 | Deutsch | Français
-
हिंदी | unDusdm (Karen) | 한국어 | ພາສາ
-
Llame a Relay Iowa TTY
Teléfono de texto para personas con problemas de audición, del habla y ceguera si necesita asistencia.
-
ລາວ | Pennsylfaanisch Deitsch | Русский
-
Српско-хрватски | Tagalog | ไทย | Tiếng Việt